Iron supplementation in
prevention of severe
anaemia and malaria by Baird, J. Kevin & Hoffman, Stephen L.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
U.S. Navy Research U.S. Department of Defense 
1997 
Iron supplementation in prevention of severe anaemia and 
malaria 
J. Kevin Baird 
U.S. Naval Medical Research Institute, jkevinbaird@yahoo.com 
Stephen L. Hoffman 
U.S. Naval Medical Research Institute 
Follow this and additional works at: https://digitalcommons.unl.edu/usnavyresearch 
Baird, J. Kevin and Hoffman, Stephen L., "Iron supplementation in prevention of severe anaemia and 
malaria" (1997). U.S. Navy Research. 74. 
https://digitalcommons.unl.edu/usnavyresearch/74 
This Article is brought to you for free and open access by the U.S. Department of Defense at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in U.S. Navy Research by an 
authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
THE LANCET
Vol 350 • December 20/27, 1997 1855
post-prophylaxis disease among those
who had received the drug fell from 1·8
to 1·4, which reveals a bias towards
exaggerated susceptibility in the
original estimate.
The post-treatment analyses of
Menendez do not link the observed
rebound in disease to defects in the de-
velopment of acquired immunity. Con-
founding by subpatent parasitaemia or
by intrinsic immune differences among
survivors of 1 year of treatment versus
placebo may explain the post-Delta-
prim rebound in disease. Evi-dence of
impairment of natural immunity by
chemoprophylaxis may have to await
development of an immunological test
proven to correlate with protective
immunity. What Gill4 wrote in 1914
still rings true: “Many problems in
connexion with malarial immunity
would be solved if it were possible to
measure directly the degree of
immunity possessed by man. Unfortu-
nately, this is at present impossible”.
*J Kevin Baird, Stephen L Hoffman
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hyperendemic region, Irian Jaya, who
received supervised chemoprophylaxis
for 1 year in a randomised, placebo-
controlled trial.2 The post-treatment
incidence of P falciparum among men
formerly taking chloroquine was two-
fold higher than among those on daily
primaquine or placebo;3 this difference
(p=0·03) was highest immediately after
treatment had been stopped, but
tapered to no difference within 12
weeks (p=0·11). This magnitude of
difference occurred with post-
prophylaxis anaemia or malaria in the
study by Menendez and co-workers. In
our study, the protective efficacy of
chloroquine during prophylaxis was
33% compared with placebo (p=0·50),
whereas that of primaquine was 94·5%
(95% CI 57–99). There were no
significant between-group differences in
the clinical features of first parasitaemia
after prophylaxis (frequency of physical
complaints, fever, parasite density, and
time for clearance of parasitaemia after
therapy). We rejected impaired
development of natural immunity as an
explanation for post-chloroquine
rebound of parasitaemia because no
rebound occurred among the patients
that had taken effective primaquine
prophylaxis.2 If effective
chemoprophylaxis impaired the
development of immunity, then a sharp
rebound in the primaquine group
should have occurred. Our
interpretation of the initially higher rate
of parasitaemia after chloroquine
therapy was the emergence of
accumulated subpatent parasitaemias
suppressed but not cleared by the drug.
A similar process may explain all or part
of the findings of Menendez and
colleagues.
Another explanation for the post-
Deltaprim rebound in anaemia may be
a selection bias in the post-treatment
follow-up groups. In their primary
analysis, the investigators included
individuals “who had not been
withdrawn from the study, and had
therefore completed the
supplementation scheme (ie, had not
been diagnosed as having severe
anaemia)”. If some children are more
susceptible to developing severe
anaemia than others, and if these
children are also more susceptible to
clinical malaria, then they would have
been selectively eliminated from the
placebo group. By contrast, the
children on Deltaprim would have been
protected from such a selection process.
Thus, the populations compared for
post-treatment susceptibility to disease
may not be directly comparable. When
Menendez and co-workers included
individuals with anaemia during the
treatment period, the relative risk of
three other small studies, presented at
the First International Symposium on
Angiotensin II Antagonism (London,
Sept 20–Oct 1, 1997), recorded
significant reductions in left-ventricular
hypertrophy in patients treated with
losartan, as indeed did the original
substudy by Himmelmann et al.5
Several large, well-designed clinical
trials, such as LIFE (Losartan
Intervention for Endpoint Reduction in
Hypertensin) are underway and should
provide definitive information on the
effects of different treatment regimens,
including those of AII antagonists, on
LVH. Until these studies are complete,
conclusions from inappropriately
designed small studies must be
considered premature.
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SIR—Clara Menendez and colleagues
(Sept 20, p 844)1 show the protective
effect of Deltaprim (3·125 mg
pyrimethamine plus 25 mg dapsone) in
infants exposed to intense transmission
of Plasmodium falciparum. On the basis
of post-treatment attack rates, they
state, “The study shows that partly
effective malaria control has modified
the rate at which naturally acquired
immunity develops”. We offer two
alternative explanations.
First, ineffective chemoprophylaxis
can lead to increased risk of
parasitaemia after discontinutation of
drug treatment due to the emergence of
accumulated parasitaemias. Second,
the attrition of intrinsically susceptible
individuals on placebo could create the
illusion of enhanced post-treatment
susceptibility among individuals
protected from such a process.
We studied 126 non-immune
transmigrants from Java living in a
SIR—Does severity of malaria decrease
with age? Is there a vulnerable period for
children living in endemic areas where
they are more susceptible to severe
disease? Is the length of it dependent on
the intensity of transmission? These are
some of the questions that can be asked
after reading Clara Menendez and
colleagues’ report.1 The main findings of
this trial are: iron supplementation
decreases the frequency of severe
anaemia (packed-cell volume <25%) but
had no effect on the frequency of clinical
malaria; weekly chemoprohylaxis with
dapsone and pyrimethamine decreases
both the frequency of clinical malaria
and severe anaemia; and after stopping
chemoprophylaxis, children who had
received it had higher rates of severe
anaemia and clinical malaria, although
the rates of all-cause and malaria-
specific hospital admissions were similar
to the other treatment groups.
